Emyria (EMD) Q1 2027 earnings summary

Executive summary

• September-quarter revenue reached a record AUD 1.42m as the Empax network expanded into NSW; five sites across four states now provide 18 beds and capacity for 90 weekly dosing sessions.

• More than 160 patients have been treated since Australia’s 2023 regulatory pathway enabled psychedelic-assisted therapy for PTSD and treatment-resistant depression.

• National, drug- and indication-agnostic clinic network under development, with international commercial opportunities also being explored.

Financial highlights

• Quarterly revenue was AUD 1.42m, versus $0.47m in the September 2025 quarter; ~$725,000 of earned revenue remained to be received as cash.

• Customer receipts were $1.597m and net operating cash outflow was $2.282m, reflecting investment in national operations, workforce readiness and medication reserves.

• Cash and cash equivalents ended the quarter at $4.745m, equivalent to 2.08 quarters of funding at the reported operating cash outflow rate.

Outlook and guidance

• Priorities include growing clinic utilisation and Sydney patient numbers, recruiting and training therapists, assessing Australian sites, and commencing DVA-funded veteran treatments.

• More than 40 DVA referrals were in screening and application; first eligible approvals arrived after quarter end, with initial treatments being prepared.

• Exploring US commercial partnerships using clinical expertise and delivery workflows, alongside opportunities in Europe and Britain.

• Late-stage discussions with an international pharmaceutical sponsor could add a second participant to the Empax Global Partnership Program.